Enveda Biosciences raises $311M to advance AI-designed drugs for immune diseases and obesity
Enveda Biosciences secures $311M in Series E funding to progress its AI-designed drug pipeline, including treatments for eczema and obesity.
Immune diseases
Latest Immune diseases coverage.